Share this article

Avellino Lab USA has introduced a new multi-panel RT-PCR-based virus assay, AvellinoCoV2 – Respiratory Test.

From a single sample, the new assay is designed to detect four viral infections, namely Covid-19, respiratory syncytial virus (RSV), influenza A and influenza B.

The company stated that the assay’s new expanded panel comes with 100% sensitivity for the detection of RSV and influenza A and B, as well as more than 99% accuracy for RSV and 100% accuracy for influenza A and B.

The Covid-19 panel in the AvellinoCoV2 – Respiratory Test analyses the N gene and can identify the presence of the Omicron variant, including BA.2, along with all other known variants of the virus.

Additionally, the new assay has the capability to detect flurona, which is a term used for a Covid-19 and influenza co-infection, or any other combination of the detectable viruses.

Last month, the first cases of flurona were detected in the US states of Texas and California.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData

Avellino chief scientific officer Nazneen Aziz said: “We are in an unprecedented cold and flu season, with Covid-19, RSV and the emerging flurona infections as continued health hazards.

“The expanded AvellinoCoV2 – Respiratory Test supports the Centers for Disease Control and Prevention’s (CDC) notice last June to expand RSV testing, as well as the physician need to test for both Covid-19 and influenza, which is now even more important with the emergence of flurona.

“With accurate and early diagnosis medical care professionals can make appropriate patient management decisions and better utilise medical resources.”

Besides a rapid antigen Covid-19 test that can identify the SARS CoV-2 presence, the firm distributes an antibody test kit that detects the presence of Covid-19 S protein antibodies, which can be acquired through vaccinations or earlier SARS-CoV-2 infections.

Through whole-genome sequencing of positive samples in its database, Avellino also undertakes surveillance of the several variants circulating in the community.

The company stated that the test samples, which are collected using a mid-turbinate nasal swab, will be sent to a Clinical Laboratory Improvement Amendments (CLIA) certified Avellino laboratory for analysis.